Skip to content
Home/Companies/Biotech/Moleculent

Moleculent

Biotech·Sweden·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Moleculent?

Moleculent is a Swedish Biotech company, currently owned by Eir Ventures since 2024.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Eir Ventures
Investor
Eir Ventures
Eir Ventures I · 2020 · Life Sciences VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Eir Ventures I

Other portfolio companies in the same fund.

Purpose Pharma
Active
PharmaSweden· 2024
Dania Tx
Active
BiotechDenmark· 2023
GutCRINE
Active
BiotechDenmark· 2023
RAPP
Active
HealthTechSweden· 2023
Scenic Biotech
Scenic Biotech
Active
BiotechNetherlands· 2023
Attgeno
Active
BiotechSweden· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Moleculent?

Moleculent is currently owned by Eir Ventures, through Eir Ventures I, since 2024.

When did Eir Ventures acquire Moleculent?

Eir Ventures acquired Moleculent in 2024.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue